118 related articles for article (PubMed ID: 1286045)
1. A combination of mitoxantrone, etoposide and prednisone in elderly patients with non-Hodgkin's lymphoma.
Salvagno L; Contu A; Bianco A; Endrizzi L; Schintu GM; Olmeo N; Aversa SM; Chiarion-Sileni V; Sorarù M; Fiorentino MV
Ann Oncol; 1992 Dec; 3(10):833-7. PubMed ID: 1286045
[TBL] [Abstract][Full Text] [Related]
2. Prednimustine, mitoxantrone (PmM) vs cyclophosphamide, vincristine, prednisone (COP) for the treatment of advanced low-grade non-Hodgkin's lymphoma. German Low-Grade Lymphoma Study Group.
Unterhalt M; Herrmann R; Tiemann M; Parwaresch R; Stein H; Trümper L; Nahler M; Reuss-Borst M; Tirier C; Neubauer A; Freund M; Kreuser ED; Dietzfelbinger H; Bodenstein H; Engert A; Stauder R; Eimermacher H; Landys K; Hiddemann W
Leukemia; 1996 May; 10(5):836-43. PubMed ID: 8656680
[TBL] [Abstract][Full Text] [Related]
3. Mitoxantrone, etoposide, cytarabine and prednisone as salvage therapy for refractory non-Hodgkin lymphoma (NHL) and alternated with CHOP in previously untreated patients with NHL.
Merk K; Ideström K; Johansson B; Kimby E; Lindemalm C; Osby E; Björkholm M
Eur J Haematol; 1991 Jan; 46(1):33-7. PubMed ID: 1988304
[TBL] [Abstract][Full Text] [Related]
4. The rationale of therapy with mitoxantrone in non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Co-operative Study Group, (NHLCSG) Italy.
Chisesi T
Leuk Lymphoma; 1993 Jan; 9(1-2):63-9. PubMed ID: 8477203
[TBL] [Abstract][Full Text] [Related]
5. Etoposide, mitoxantrone and prednisone: a salvage regimen with low toxicity for refractory or relapsed non-Hodgkin's lymphoma.
Doorduijn JK; Spruit P; van Der Holt B; van't Veer M; Budel L; Löwenberg B; Sonneveld P
Haematologica; 2000 Aug; 85(8):814-9. PubMed ID: 10942927
[TBL] [Abstract][Full Text] [Related]
6. A prospective study of a new combination chemotherapy regimen in patients older than 70 years with unfavorable non-Hodgkin's lymphoma.
Tirelli U; Zagonel V; Errante D; Serraino D; Talamini R; De Cicco M; Carbone A; Monfardini S
J Clin Oncol; 1992 Feb; 10(2):228-36. PubMed ID: 1732423
[TBL] [Abstract][Full Text] [Related]
7. Reduced-dose cladribine (2-CdA) plus mitoxantrone is effective in the treatment of mantle-cell and low-grade non-Hodgkin's lymphoma.
Rummel MJ; Chow KU; Karakas T; Jäger E; Mezger J; von Grünhagen U; Schalk KP; Burkhard O; Hansmann ML; Ritzel H; Bergmann L; Hoelzer D; Mitrou PS
Eur J Cancer; 2002 Sep; 38(13):1739-46. PubMed ID: 12175690
[TBL] [Abstract][Full Text] [Related]
8. Intensive sequential chemotherapy with repeated blood stem-cell support for untreated poor-prognosis non-Hodgkin's lymphoma.
Stoppa AM; Bouabdallah R; Chabannon C; Novakovitch G; Vey N; Camerlo J; Blaise D; Xerri L; Resbeut M; Di Stefano D; Bardou VJ; Gastaut JA; Maraninchi D
J Clin Oncol; 1997 May; 15(5):1722-9. PubMed ID: 9164178
[TBL] [Abstract][Full Text] [Related]
9. Equitoxicity of bolus and infusional etoposide: results of a multicenter randomised trial of the German High-Grade Non-Hodgkins Lymphoma Study Group (DSHNHL) in elderly patients with refractory or relapsing aggressive non-Hodgkin lymphoma using the CEMP regimen (cisplatinum, etoposide, mitoxantrone and prednisone).
Zwick C; Birkmann J; Peter N; Bodenstein H; Fuchs R; Hänel M; Reiser M; Hensel M; Clemens M; Zeynalova S; Ziepert M; Pfreundschuh M;
Ann Hematol; 2008 Sep; 87(9):717-26. PubMed ID: 18587579
[TBL] [Abstract][Full Text] [Related]
10. A brief-duration combination chemotherapy for elderly patients with poor-prognosis non-Hodgkin's lymphoma.
McMaster ML; Johnson DH; Greer JP; Wolff SN; Hildreth CR; Greco FA; Hainsworth JD
Cancer; 1991 Mar; 67(6):1487-92. PubMed ID: 1705861
[TBL] [Abstract][Full Text] [Related]
11. Ifosfamide, mitoxantrone and etoposide (VIM) as salvage therapy of low toxicity in non-Hodgkin's lymphoma.
Hopfinger G; Heinz R; Koller E; Schneider B; Pittermann E
Eur J Haematol; 1995 Oct; 55(4):223-7. PubMed ID: 7589338
[TBL] [Abstract][Full Text] [Related]
12. Mesna/ifosfamide, mitoxantrone, etoposide, bleomycin, vincristine, prednisone (MINE-BOP) combination chemotherapy in the treatment of refractory and relapsed non-Hodgkin's lymphoma.
Dinçol D; Içli F; Karaoğuz H; Cay F; Arican A; Demirkazik A; Akbulut H
Acta Oncol; 1995; 34(7):937-40. PubMed ID: 7492384
[TBL] [Abstract][Full Text] [Related]
13. A new protocol (MiCEP) for the treatment of intermediate or high-grade non-Hodgkin's lymphoma in the elderly.
Bellesi G; Rigacci L; Alterini R; Bernardi F; Stefanacci S; Innocenti F; Fusco II; Longo G; Di Lollo S; Ferrini PR
Leuk Lymphoma; 1996 Feb; 20(5-6):475-80. PubMed ID: 8833406
[TBL] [Abstract][Full Text] [Related]
14. Salvage chemotherapy with mitoxantrone, fludarabine, cytarabine, and cisplatin (MIFAP) in relapsing and refractory lymphoma.
Hänel M; Kröger N; Kroschinsky F; Birkmann J; Hänel A; Herbst R; Naumann R; Friedrichsen K; Ehninger G; Zander AR; Fiedler F
J Cancer Res Clin Oncol; 2001; 127(6):387-95. PubMed ID: 11414199
[TBL] [Abstract][Full Text] [Related]
15. Salvage chemotherapy for non-Hodgkin's lymphoma with a combination of mitoxantrone, etoposide, cisplatin, and prednisolone.
Ohnoshi T; Hayashi K; Ueoka H; Yamane T; Ueno K; Murashima M; Tada A; Yoshida M; Kimura I
Cancer Treat Rep; 1987 Jun; 71(6):639-41. PubMed ID: 3581103
[TBL] [Abstract][Full Text] [Related]
16. Second-line chemotherapy in human immunodeficiency virus-related non-Hodgkin's lymphoma: evidence of activity of a combination of etoposide, mitoxantrone, and prednimustine in relapsed patients.
Tirelli U; Errante D; Spina M; Gastaldi R; Nigra E; Nosari AM; Magnani G; Vaccher E
Cancer; 1996 May; 77(10):2127-31. PubMed ID: 8640681
[TBL] [Abstract][Full Text] [Related]
17. CEOP-B alternated with VIMB in intermediate-grade and high-grade non-Hodgkin's lymphoma: a pilot study.
De Lena M; Ditonno P; Lorusso V; Brandi M; Timurian A; Marzullo F; Ventrella V; Pellecchia A
J Clin Oncol; 1995 Apr; 13(4):953-60. PubMed ID: 7535844
[TBL] [Abstract][Full Text] [Related]
18. A comparative study of CHOP versus MEVP (mitoxantrone, etoposide, vindesine, prednisolone) therapy for intermediate-grade and high-grade non-Hodgkin's lymphoma: a prospective randomized study.
Takagi T; Sampi K; Sawada U; Sakai C; Oguro M
Int J Hematol; 1993 Jan; 57(1):67-71. PubMed ID: 8477064
[TBL] [Abstract][Full Text] [Related]
19. Phase II study of lomustine, cytarabine, mitoxantrone, and prednisone (CAMP) combination chemotherapy for doxorubicin-resistant intermediate- and high-grade malignant non-Hodgkin's lymphoma.
Ruit JB; Löwenberg B; Hagenbeek A; Verhoef GE; Wielenga JJ; Michiels J; Sizoo W
Semin Oncol; 1990 Dec; 17(6 Suppl 10):24-7. PubMed ID: 2259920
[TBL] [Abstract][Full Text] [Related]
20. Vincristine, doxorubicin, cyclophosphamide, prednisone and etoposide (VACPE) in high-grade non-Hodgkin's lymphoma--a multicenter phase II study.
Bergmann L; Karakas T; Lautenschlager G; Jager E; Knuth A; Mitrou PS; Hoelzer D
Ann Oncol; 1995 Dec; 6(10):1019-24. PubMed ID: 8750155
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
